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Abstract
Background: Orphan designated medicinal products benefit from regulatory and economic incentives for orphan
drug development. Approximately 40% of orphan designations target rare neoplastic disorders, referring to rare
cancers. In order to provide more insights in drugs for rare neoplastic disorders that are under development and to
better understand the role of orphan designation in the development of oncology drugs, this study investigates the
characteristics of the product, the indication and the applicants as well as the stage of development of products with
an orphan designation for rare neoplastic disorders and compares them with products with an orphan designation for
other rare indications. Therefore, orphan designation application files and annual reports submitted by the applicant
were reviewed at the premises of the European Medicines Agency.
Results: At the time of application, 41.6% of products with orphan designation for rare neoplastic disorders were in
pre-clinical phase; this was 65.1% for other rare conditions (p < 0.05). Thirty percent of orphan designations for rare
neoplastic disorders had reached phase 1; compared to 19.3% of orphan designations targeting other rare conditions
(p < 0.05). The same trend was observed for the stage of development at the time of the latest annual report.
Significant benefit was more often considered for orphan designations for rare neoplastic disorders compared to
orphan designations for other rare conditions.
Conclusion: Orphan designations for rare neoplastic disorders involve products that are in a more advanced stages of
development compared to orphan designations for other (non-oncology) rare conditions.
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Background
Rare cancers affect around 4.3 million persons in the
European Union (EU) and more than 500,000 new cases
are diagnosed every year [1]. Despite the small number
of patients per indication, rare cancers now represent a
significant number of the total burden of cancer, with
22% of all cancer cases diagnosed in the EU each year
considered as ‘rare’ [2].
In 2000, the European Commission (EC) introduced
the Regulation on Orphan Medicinal Products (OMP) to
provide regulatory and economic incentives for orphan
drug development [3]. OMP designations can be assigned
to medicinal products prior to marketing authorization,
on the condition that the product is intended for diagno-
sis, prevention or treatment of a life-threatening or chron-
ically debilitating condition that affects less than 5 in
10,000 persons in EU or when marketing is unlikely due
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to insufficient return on investment. Further, should there
be no satisfactory method of diagnosis, prevention or
treatment of the condition that has been authorized in
Europe, or if such methods exist, that the medicinal prod-
uct requesting OMP designation offers significant benefits
compared to existing treatments [3]. Many incentives have
been introduced with the OMP legislation [3]. Medicinal
products with OMP designation have access to a reduced
fee for a specific scientific advice procedure, called
protocol assistance. Whereby scientific advice provides a
sponsor with guidance on regulatory requirements for the
demonstration of quality, safety and efficacy of the drug,
protocol assistance can additionally answer questions with
regard to the significant benefit criterion for OMP desig-
nation. Protocol assistance is free of charge for registered
Small and Medium sized Enterprises (SMEs) [3]. Further,
medicinal products with OMP designation benefit from a
reduction in the regular fee for the centralized procedure
for marketing authorization and are protected by a
10-year market exclusivity period from the moment that
marketing authorization is granted from similar medicinal
products [3]. A single medicinal product can obtain an
OMP designation for multiple conditions and an OMP
designation can be granted to multiple medicinal products
targeting the same oncological indication. When desig-
nated as an OMP, sponsors are obliged to provide yearly
reports on progress of drug development [3]. By 2015,
over 1500 OMP designations were granted based on a
positive opinion from the Committee for Orphan
Medicinal Products (COMP), over 100 OMPs received
marketing authorization in Europe.
The high burden of rare cancers shows the need for
accessible and effective drugs to treat these diseases. A
previous study already showed a promising OMP pipe-
line where rare neoplastic disorders represent an import-
ant share of the indications, however, the pipeline for
OMP that intent to treat cancer was not specifically
investigated in this study [4]. OMP designation seems an
important track for oncology drug development since
approximately 40% of all OMP designations and an
equal number of authorized OMPs target rare cancers
[4, 5]. This is in contrast with the proportion of medicinal
products for non-orphan conditions, where oncology
products only represent 13% of the total number of drugs
[6]. In order to better understand the role of OMP desig-
nation in the development of oncology drugs, this study
investigates the characteristics of the product, the indica-
tion and the applicants as well as the stage of development
for OMP designations for rare cancer and compares them
with OMP designations for other rare indications.
Methods
The data for this study were collected in the context of
an analysis on the orphan drug pipeline across all
indications. Additional methodological details can be
found elsewhere [4].
OMP designations fulfilling the following conditions
were included in this study: OMP designation was
granted between January 1st 2002 and December 31st
2012, designation was valid on June 13th 2014, no
marketing authorization was granted by the EC over the
study period. The Community Register of OMP for
human use and Orphadata, the scientific dataset devel-
oped and managed by Orphanet, were consulted to
determine the study sample. Data were collected at the
premises of the European Medicine Agency (EMA) in
London during November 2014.
The following variables were used for this study: year
of application, designation year, designated orphan indi-
cation, Orphanet© linearization disease category, type of
product (gene therapy, ingredient/substance, cell therapy
product, human/animal tissue/organ, blood derived
product) and type of production (e.g. biotechnology or
synthetic/extractive chemistry), applicant categorization
(academia/public body, physical persons, consulting,
small pharma, medium pharma, large pharma or SME),
prevalence of the indication, use of significant benefit
criterion by EMA at the time of application, status of
drug development at time of application and at the time
of the latest annual report.
Applicants were categorized based on Amadeus
database [4]. Academia/public bodies, consulting and
physical persons were identified by website search. The
Amadeus© (Bureau van Dijk) database of financial and
business information was consulted to categorize private
sponsors based on annual operating revenue. Sponsors
with an annual operating revenue above €25 billion were
assigned to the group of very large pharmaceutical com-
panies. If the annual operating revenue was between €24
billion and €6 billion, the sponsor was categorized as be-
ing “large”. Less than €5 billion revenue was allocated to
“intermediate sized companies” and less than €50 million
was allocated in “small or medium-sized enterprise”
(SME). SME’s are defined by the EC based on turnover
and staff headcount, however, in this study, staff head-
count was not considered for the categorization.
The prevalence of the indication was retrieved from
the application file submitted by the applicant to EMA
and segmented in three categories i.e. high prevalence
(>3/10,000), medium prevalence (1–3/10,000) and low
prevalence (<1/10,000).
When designated as an OMP, sponsors are obliged to
provide yearly reports on progress of drug development.
While the status of drug development at the time of
OMP designation can contribute to understanding the
role of OMP designation for rare neoplastic disorders,
the stage of development in the annual report allows in-
sights in the OMP pipeline for rare neoplastic disorders,
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complementary to a previous study on OMP pipeline in
general [4]. In case data about the state of drug develop-
ment could not be retrieved from the most recent
annual report, the report that was provided during the
previous reporting period was used. Missing data were
reported if appropriate data were not available in the
most recent and previous reports. Status of drug devel-
opment was classified in pre-clinical research, phase 0,
phase I, phase II and phase III and compassionate use
(CU) studies. Annual reports are specific to each desig-
nation. As a consequence, when one active substance is
the subject of several designations, a separate report was
prepared for each designation.
OMP designations were categorized in a group for rare
cancers, further referred as rare neoplastic disorders and
a group for other rare conditions, based on Orphanet©
linearization disease category. The proportion of desig-
nations that belong to a certain category of product type,
applicant category, prevalence category, consideration of
significant benefit criterion and stage of development re-
ported in the application file and the latest annual report
were compared between designations for rare neoplastic
disorders versus designations for other rare conditions
using Chi2 test. A 0.05 confidence level was considered.
Analysis was performed in IBM Statistics SPSS 23.
Results
Information on 730 designations was collected. Of these
designations, 269 (36.8%) involved rare neoplastic
disorders and 461 (63%) involved other rare conditions.
The number of conditions for which positive opinion on
OMP designation was granted increased over time, from
20 conditions in 2002 to 140 conditions in 2012 (Fig. 1).
The proportion of ODs targeting rare neoplastic disor-
ders over total ODs has been slightly decreasing over
the study period 2002 to 2012 (Fig. 1). While in 2002,
45% of the OMP designations involved rare neoplastic
disorders, only 31% of OMP designations were granted
for rare neoplastic disorders in 2012.
There was no significant difference in product type be-
tween products that obtained OMP designation for rare
neoplastic disorders and products that obtained a desig-
nation for other rare conditions (Table 1). More than
half of the designations for rare neoplastic disorders was
applied for by SME’s. Although SME’s also compose the
majority of applicants for other rare conditions, their
involvement was significantly lower compared to in rare
neoplastic disorders (Table 1). On the other hand, desig-
nations for rare neoplastic disorders were never applied
by academia or public bodies and only in singly cases
applied for by physical persons. Although the number of
applications from this group for other rare conditions
was still small, the difference with rare neoplastic disor-
ders was significant (Table 1).
Almost 70% of rare neoplastic disorders had a preva-
lence of one to three persons in a population of 10,000.
This was significantly different from the indication of
other rare conditions as in this group, almost half of the
designations involved an indication that occurred less
than 1 time in 10,000 persons (Table 1).
While the significant benefit criterion was considered
in 75% of OMP designations granted for rare neoplastic
Fig. 1 Number of orphan designations for rare neoplastic disorders in relation to the total number of designations between 2002 and 2012
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disorders, less than half of the designations for other
rare conditions included an assessment of the significant
benefit of the product (Table 1).
At the time of application for an OMP designation,
the majority of products for rare neoplastic disorders
already reached the clinical development stage. This
is in contract to products for other rare indications
were more than half of the products still remain in
pre-clinical phases (Fig. 2). At the time of the most
recent annual report, only one third of products for
other rare conditions is still in pre-clinical develop-
ment, however, the proportion of products for rare
neoplastic disorders in pre-clinical development is less
than 10% (Fig. 3).
There was no significant relationship between preva-
lence segmentation and stage of development.
Significant differences were observed in the stage of
development of the products between different categories
of applicants. OMP designations for rare neoplastic disor-
ders were more often applied for based on phase 2 studies
by SME’s, medium pharma, large pharma and very large
pharma compared to physical persons. There was no
significant difference across different applicant sizes for
the proportion of OMP designations applied for based on
non-clinical data, phase 1 or phase 3 studies (data not
shown).
OMP designations for other rare conditions were more
often applied for based on non-clinical data by large
pharma compared to very large pharma. Medium pharma,
SME, consulting, physical persons and academia more
frequently used non-clinical data when applying OMP
designation for other rare conditions, while there was no
significant difference between very large pharma and large
pharma (data not shown).
Discussion
This study provides insights in the pipeline for OMP for
rare neoplastic disorders and the role of OMP designa-
tion in the development of oncology drugs. Previous
analysis showed that the majority of OMP designations
across all conditions was granted a positive opinion
based on preliminary clinical data with the product in
patients with the condition, with only around 30% of
submissions that show medical plausibility based on in
vivo data only [4, 7]. Our study showed that the
proportion of products in preclinical phase was much
lower for rare neoplastic disorders compared to other
rare indications. An analysis on the orphan drug pipeline
in general estimated that between 90 and 100 products
of the sample can reach marketing authorization in the
future [4]. Based on the results of this study, however, it
is still unsure whether the more advanced stage of
development of OMP designation for rare neoplastic
disorders are also associated with higher success rates
for marketing authorization. The following section will
discuss reasons that might explain the observed results.
Consideration of significant benefit for products that is
intented to treat rare neoplastic disorders, suggest that
alternative treatments exist more often for these diseases
compared to other rare conditions. Over the last decade,
technological evolutions in the field of microscopy,
molecular biology and genomics led to improved under-
standing of the mechanisms behind cancer. In parallel
with these technological evolutions, a competitive mar-
ket with multiple therapeutic options per indication was
established and today, the market is still evolving [8].
The presence of twelve centrally authorized products to
treat multiple myeloma can illustrate this, and more is yet
to come since multiple myeloma/plasma cell myeloma
(terminology used interchangeably) is also the subject of
20 OMP designations which are still active by October
2016 [6].
Uncertainties about safety and efficacy will be less ac-
ceptable when alternative products are already available.
In addition quality, safety and efficacy requirements of
the drug, evidence for significant benefit is a require-
ment for OMP designation but also necessary to confirm
at the time of market authorization. Incentives for devel-
opment of OMP such as protocol assistance can support
applicants at the moment they approach the stage of
Table 1 Comparison product type, applicant categorization,
prevalence segmentation and consideration of significant
benefit criterion for products that obtained OMP designations
for rare neoplastic disorders and products that obtained OMP
designation for other rare conditions
Rare neoplastic
disorders (N = 269)
Other rare
conditions (N = 461)
Product type
Synthetic/extractive agent 53.5% (144) 53.8% (248)
Biotechnology 46.5% (125) 46.2% (213)
Applicant categorization
Academia/Public body 0% (0)a 4% (20)a
Consulting 9% (25) 11% (52)
Physical person 2% (6)a 6% (27)a
SME 56% (150)a 47% (216)a
Intermediate sized company 13% (35) 16% (75)
Large Pharma 13% (35)a 7% (31)a
Very large Pharma 7% (18) 9% (40)
Prevalence segmentation
< 1/10,000 19% (51) 47.7%(220)
1–3/10,000 69.1% (186)a 41.4% (191)a
> 3/10,000 11.9% (32)a 10.8% (50)a
Consideration of significant benefit criterion
Yes 75.1% (202)a 44.3% (204)a
aIndicates difference at 0.05 level based on Chi2 test
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clinical development where they need to compete with
alternative treatments for which experience is already
gained after marketing authorization. Protocol assistance
can also aid towards generation of appropriate data to
substantiate marketing authorization later on.
Registered SME obtain free protocol assistance upon
OMP designation. Our study showed a significant differ-
ence in the proportion of SME sponsoring OMP desig-
nated products, but categorization of companies is based
on Amadeus database, different from criteria applied by
the European Commission. Although some differences
in company size were observed between sponsors of
OMP designations for rare neoplastic disorders versus
other conditions, there was no general trend towards lar-
ger companies in the group of rare neoplastic disorders.
Our results indicate that for rare neoplastic disorders,
clinical data are achievable even for smaller sized compan-
ies as phase II clinical data for rare neoplastic disorders
Fig. 3 Orphan designations at time of latest annual report, described by stage of development. *Indicates significant differences at the 0.05 level
Fig. 2 Orphan designations at time of application, described by stage of development. *Indicates significant differences at the 0.05 level
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were equally available for smaller sized companies
compared to medium and large size companies. It can be
hypothesizes whether the transition from pre-clinical
studies towards clinical studies is easier for rare neoplastic
disorders compared to other rare indications. On the one
hand, this can be due to technological evolutions and
abundant experience in the disease domain, allowing bet-
ter understanding of neoplastic disease and mechanisms
behind therapeutic agents. In some cases, clinical experi-
ence with an authorized product (which can even be the
same product with a marketing authorization in another
indication) using the same mechanism of action as the
one applying for OD may already be available. Experiences
in a broad indication can be used in limited patient popu-
lations were efficacy is increased. Conditions other than
those for neoplastic disorders are often less known and
less understood. On the other hand, the questions raises
whether the benefit-risk ratio that is accepted within
clinical trials for rare neoplastic disorders is the same for
other rare neoplastic conditions.
As the reasons for the findings in this study are
unknown, the authors hypothesis that competition may
complicate demonstration of significant benefit based on
pre-clinical data, and therefore OMP designations for
rare neoplastic disorders are more likely to be applied at
the stage of clinical development. This may also suggest
that significant benefit for rare neoplastic disorders can
go beyond mechanisms of action, tumor response,
cellular toxicity and survival but involve patient relevant
outcomes that can only be proven based on clinical data.
This study is subject to two limitations. First, the study
data are limited to OMP designations granted between
2002 and 2012. In order to include data from the annual
report, a timespan of at least one year is required between
the moment that the orphan designation is granted and
the moment that data are collected. Nevertheless, new or-
phan designations were granted in the time between the
data collection and publication of these results. Second, the
data of this study only include submission for orphan des-
ignation for which a positive decision was granted. There-
fore, we cannot draw conclusions on factors that play a
determinative role in the provision of orphan designations,
neither on the success factors to prove significant benefit.
An updated dataset that is extended towards unsuccessful
submission for OMP designations could further contribute
to understanding the role of the OMP Regulation in the
development of oncology drugs and provide valuable
knowledge to policymakers, payers and industry that is
essential to reduce the burden of rare cancers in Europe.
Conclusion
At time of data analysis, products with OMP designation
are in a more advanced stage of development when they
intent to treat rare neoplastic disorders than when they
intent to treat other rare indications. The competitive
character of the oncology market in combination with the
requirement of significant benefit for OMP designations
are a potential explanation for the observed results.
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